Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2025-12-26 @ 11:46 PM
Study NCT ID:
NCT00520650
Status:
COMPLETED
Last Update Posted:
2009-12-16
First Post:
2007-08-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Health Evaluation of Abilify Long-term Therapy
Sponsor:
Taiwan Otsuka Pharm. Co., Ltd
Organization:
Study Overview
Official Title:
Health Evaluation of Abilify Long-term Therapy
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEALTH
Brief Summary:
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment. The health profiles during the switching period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will be recorded and evaluated.
Detailed Description:
Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: